Zymeworks Inc. Common Shares (ZYME): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZYME POWR Grades
- Growth is the dimension where ZYME ranks best; there it ranks ahead of 51.86% of US stocks.
- ZYME's strongest trending metric is Momentum; it's been moving down over the last 179 days.
- ZYME ranks lowest in Stability; there it ranks in the 5th percentile.
ZYME Stock Summary
- With a year-over-year growth in debt of 278.23%, Zymeworks Inc's debt growth rate surpasses 95.7% of about US stocks.
- As for revenue growth, note that ZYME's revenue has grown -31.5% over the past 12 months; that beats the revenue growth of only 5.32% of US companies in our set.
- The volatility of Zymeworks Inc's share price is greater than that of 96.98% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Zymeworks Inc are ARDS, CDTX, IVA, XCUR, and AUTL.
- ZYME's SEC filings can be seen here. And to visit Zymeworks Inc's official web site, go to www.zymeworks.com.
ZYME Valuation Summary
- In comparison to the median Healthcare stock, ZYME's price/earnings ratio is 118.9% lower, now standing at -6.9.
- ZYME's EV/EBIT ratio has moved up 2.5 over the prior 53 months.
- ZYME's EV/EBIT ratio has moved up 2.5 over the prior 53 months.
Below are key valuation metrics over time for ZYME.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ZYME | 2021-08-31 | 73.8 | 4.8 | -6.9 | -5.9 |
| ZYME | 2021-08-30 | 72.8 | 4.7 | -6.8 | -5.8 |
| ZYME | 2021-08-27 | 73.5 | 4.7 | -6.9 | -5.8 |
| ZYME | 2021-08-26 | 71.5 | 4.6 | -6.7 | -5.7 |
| ZYME | 2021-08-25 | 72.9 | 4.7 | -6.8 | -5.8 |
| ZYME | 2021-08-24 | 73.8 | 4.8 | -6.9 | -5.9 |
ZYME's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ZYME has a Quality Grade of D, ranking ahead of 18.34% of graded US stocks.
- ZYME's asset turnover comes in at 0.047 -- ranking 324th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ZYME's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.047 | 1 | -1.423 |
| 2021-06-30 | 0.040 | 1 | -1.267 |
| 2021-03-31 | 0.057 | 1 | -0.902 |
| 2020-12-31 | 0.066 | 1 | -0.661 |
| 2020-09-30 | 0.046 | 1 | -0.832 |
| 2020-06-30 | 0.060 | 1 | -0.772 |
ZYME Stock Price Chart Interactive Chart >
ZYME Price/Volume Stats
| Current price | $5.82 | 52-week high | $39.41 |
| Prev. close | $5.17 | 52-week low | $4.56 |
| Day low | $5.11 | Volume | 2,788,300 |
| Day high | $6.07 | Avg. volume | 1,589,165 |
| 50-day MA | $6.22 | Dividend yield | N/A |
| 200-day MA | $16.88 | Market Cap | 336.23M |
Zymeworks Inc. Common Shares (ZYME) Company Bio
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company was founded in 2003 and is based in Vancouver, BC.
Latest ZYME News From Around the Web
Below are the latest news stories about Zymeworks Inc that investors may wish to consider to help them evaluate ZYME as an investment opportunity.
Zymeworks Inc. 2021 Q4 - Results - Earnings Call PresentationThe following slide deck was published by Zymeworks Inc. in conjunction with their 2021 Q4 earnings call.... |
Zymeworks Inc. (ZYME) CEO Kenneth Galbraith on Q4 2021 Results - Earnings Call TranscriptStart Time: 16:30 End Time: 17:19 Zymeworks Inc. (ZYME) Q4 2021 Earnings Conference Call February 24, 2022, 16:30 PM ET Company Participants Kenneth Galbraith - Chair and CEO Chris Astle - SVP and CFO Neil Klompas - COO Neil Josephson - CMO Jack Spinks - Manager of IR Conference Call... |
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial ResultsVANCOUVER, British Columbia & SEATTLE, February 24, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2021 and provided a summary of recent business highlights. |
Zymeworks Q4 2021 Earnings PreviewZymeworks (NYSE:ZYME) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is -$1.13 (-82.3% Y/Y) and the consensus… |
Earnings Preview: Zymeworks Inc. (ZYME) Q4 Earnings Expected to DeclineZymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
ZYME Price Returns
| 1-mo | 8.99% |
| 3-mo | -18.94% |
| 6-mo | -70.62% |
| 1-year | -80.35% |
| 3-year | -68.14% |
| 5-year | -55.37% |
| YTD | -64.49% |
| 2021 | -65.32% |
| 2020 | 3.96% |
| 2019 | 209.67% |
| 2018 | 93.41% |
| 2017 | N/A |
Continue Researching ZYME
Here are a few links from around the web to help you further your research on Zymeworks Inc's stock as an investment opportunity:Zymeworks Inc (ZYME) Stock Price | Nasdaq
Zymeworks Inc (ZYME) Stock Quote, History and News - Yahoo Finance
Zymeworks Inc (ZYME) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...